CN1633431A - 喹唑啉衍生物类激酶抑制剂 - Google Patents
喹唑啉衍生物类激酶抑制剂 Download PDFInfo
- Publication number
- CN1633431A CN1633431A CNA018173527A CN01817352A CN1633431A CN 1633431 A CN1633431 A CN 1633431A CN A018173527 A CNA018173527 A CN A018173527A CN 01817352 A CN01817352 A CN 01817352A CN 1633431 A CN1633431 A CN 1633431A
- Authority
- CN
- China
- Prior art keywords
- quinazoline
- piperazinyl
- phenyl
- carboxylic acid
- methoxyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 3
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- -1 nitrogen-containing heterocyclic compounds Chemical class 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000026731 phosphorylation Effects 0.000 claims abstract description 19
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 19
- 230000010261 cell growth Effects 0.000 claims abstract description 8
- 108091008606 PDGF receptors Proteins 0.000 claims abstract description 7
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims abstract description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 230000002159 abnormal effect Effects 0.000 claims abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 91
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 66
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
- 239000001301 oxygen Substances 0.000 claims description 44
- 229910052760 oxygen Inorganic materials 0.000 claims description 44
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- 241001597008 Nomeidae Species 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 241000235503 Glomus Species 0.000 claims description 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 4
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- LEJHOVHEPUDNCC-UHFFFAOYSA-N 2-isocyanatobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1N=C=O LEJHOVHEPUDNCC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 229940095102 methyl benzoate Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 230000012292 cell migration Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 21
- 102000020233 phosphotransferase Human genes 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000002792 vascular Effects 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 2
- 102000001253 Protein Kinase Human genes 0.000 abstract description 2
- 108060006633 protein kinase Proteins 0.000 abstract description 2
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 239000002585 base Substances 0.000 description 39
- 238000012360 testing method Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108010081589 Becaplermin Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 2
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- XGLJSPFXMGSGKC-UHFFFAOYSA-N 1-bromo-1-methoxyethane Chemical compound COC(C)Br XGLJSPFXMGSGKC-UHFFFAOYSA-N 0.000 description 1
- QJNRQJGEIYYPRW-UHFFFAOYSA-N 2,3-dimethoxyquinoline Chemical class C1=CC=C2N=C(OC)C(OC)=CC2=C1 QJNRQJGEIYYPRW-UHFFFAOYSA-N 0.000 description 1
- RVZMPNMUBCAPQO-UHFFFAOYSA-N 2,4-dimethoxyquinazoline Chemical class C1=CC=CC2=NC(OC)=NC(OC)=C21 RVZMPNMUBCAPQO-UHFFFAOYSA-N 0.000 description 1
- BMGMINKVTPDDRZ-UHFFFAOYSA-N 2-acetamido-n-[1-[[5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide;n-[1-[[5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methyl-2-(propanoylamino)pentanamide Chemical compound CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N.CCC(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N BMGMINKVTPDDRZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010011078 Leupeptins Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108700004203 eye-derived growth factor Proteins 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical class ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 108010028349 saliva Orthana Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及对激酶磷酸化具有抑制性,因而对此类酶具有抑制性的含氮杂环化合物及其药学上认可的盐。本发明还涉及通过抑制激酶磷酸化来抑制激酶和治疗哺乳动物疾病的方法。本发明具体内容之一是抑制PDGF受体磷酸化从而抑制异常细胞生长和迁移的含氮杂环化合物及其药学上认可的盐,以及预防或治疗诸如动脉硬化、血管再梗阻、癌症和血管球性硬化症等细胞增殖性疾病的方法。
Description
技术领域
本发明涉及抑制激酶磷酸化活性进而可抑制此类激酶活性的含氮杂环化合物及其药学上认可的盐。本发明还涉及通过抑制激酶磷酸化来抑制激酶和治疗哺乳动物疾病的方法。
背景技术
PDGF(血小板衍生类生长因子)会造成细胞增殖性疾病的恶化,例如动脉硬化,经皮冠血管再造术和血管搭桥术后的血管再梗阻,癌症,肾小球性肾炎,血管球性硬化症,牛皮癣和风湿性关节炎(细胞,46,155-169(1986);科学,253,1129-1132(1991);Nippon Rinsho(日本临床医学杂志),50,3038-3045(1992);Nephrol Dial Transplant,10,787-795(1995);Kidney International,43(Suppl.39),86-89(1993);风湿病学杂志,21,1507-1511(1994);北欧免疫学杂志,27,285-294(1988);等)。
据南非专利No.67 06512(1968)记载,在用作药物的喹唑啉衍生物中,N,N-二甲基-4-(6,7-二甲氧基-4-喹唑啉基)-1-哌嗪羧酰胺是一种支气管扩张药。据日本公开待审专利申请No.208911/93和WO96/09294报道,二甲氧基喹唑啉衍生物是表皮生长因子(EGF)受体磷酸化的抑制剂。《药物学生物化学及性能》,53,87-97(1996)和《欧洲医学化学杂志》,31,417-425(1996)报道了具有苯并二氮杂草受体抑制性的喹啉衍生物,《印度化学杂志》,26B,550-555(1987)报道了可用作抗寄生虫药的喹啉衍生物。
目前所知的PDGF受体磷酸化抑制剂包括二单环芳基化合物和双环芳基化合物和杂芳基化合物(WO92/20642),喹喔啉衍生物(《癌症研究》,54,6106(1994)),嘧啶衍生物(日本公开待审专利申请No.87834/94)和二甲氧基喹啉衍生物(日本药学协会第16届(金泽)年会摘要(1996),2,p.275,29(C2),15-2)。
发明内容
本发明目的在于提供对激酶的磷酸化作用具有抑制性进而抑制激酶活性的含氮杂环化合物及其药学上认可的盐。本发明尤其关注的激酶抑制性是对受体酪氨酸激酶的抑制性,此类受体包括血小板衍生类生长因子(PDGF)受体,Flt3,CSF-1R,表皮生长因子受体(EDGF),成纤维细胞生成因子(FGF),血管内皮生长因子受体(VEGFR)等。本发明涉及的另一类激酶抑制性是对src和abl等非受体酪氨酸激酶的抑制性。本发明涉及的第三类激酶抑制性是对丝氨酸/苏氨酸激酶的抑制性,此类激酶例如介导细胞增殖的MAPK,MEK和细胞周期蛋白(cyclin)依赖性激酶(CDKs),介导细胞存活的AKT和CDK,以及调节炎性反应的NIK。抑制此类激酶可用于治疗涉及细胞存活、增殖和迁移的疾病,例如动脉硬化和血管再梗阻之类心血管病,癌症,血管球性硬化性纤维变性疾病和炎症,以及用于对细胞增殖性疾病的一般性治疗。
优选实施方式中,本发明提供的化合物及其药学上认可的盐能够抑制或预防至少一种酪氨酸激酶对至少一种PDGF受体的磷酸化作用。这样的PDGF受体激酶抑制性可抑制异常的细胞生长和迁移,因此,此类化合物可用于预防或治疗诸如动脉硬化、血管再梗阻、癌症和血管球性硬化症等细胞增殖性疾病。
本发明涉及以下式I所示含氮杂环化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物:
其中,R1选自:-CN,-X,-CX3,-R5,-CO2R5,-C(O)R5,-SO2R5,-O-C1-8直链或支链烷基,-O-苯基,-O-萘基,-O-吲哚基和-O-异喹啉基;X是卤素;
R5是H或C1-8直链或支链烷基;
R2和R4各自选自:-O-CH3,-O-CH2-CH3,-O-CH2-CH=CH2,-O-CH2-C≡CH,-O(CH2)n-SO2-R5,-O-CH2-CH(R6)CH2-R3和-O-(CH2)n-R3;R6是-OH,-X或C1-8直链或支链烷基;
n是2或3;
R3选自:-OH,-O-CH3,-O-CH2-CH3,-NH2,-N(-CH3)2,-NH(-CH2-苯基),-NH(- 苯基),-CN,
优选式I化合物及其位置异构体、类似物,以及它们的药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物中,R1选自:-CN,-O-甲基,-O-乙基,-O-丙基,-O-异丙基,-O-丁基,-O-叔丁基,-O-异戊基,1-萘氧基,2-萘氧基,4-吲哚氧基,5-吲哚氧基,5-异喹啉氧基。
此外,优选化合物及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物中,R2与R4不同,且其中之一为-O-CH3。
式I化合物的药学上认可的盐包括其药学上认可的酸加成盐,金属盐,铵盐,有机胺盐,氨基酸加成盐等。
式I化合物的药学上认可的酸加成盐的例子是盐酸、硫酸和磷酸等无机酸的加成盐和乙酸、马来酸、富马酸、酒石酸、柠檬酸和甲磺酸等有机酸的加成盐。
药学上认可的金属盐的例子是钠盐、钾盐等碱金属盐,镁盐、钙盐等碱土金属盐,铝盐和锌盐。药学上认可的铵盐的例子是铵盐和四甲基铵盐。药学上认可的有机胺加成盐的例子有吗啉盐和哌啶盐等杂环胺盐。药学上认可的氨基酸加成盐的例子是赖氨酸盐、甘氨酸盐和苯丙氨酸盐。
优选实施方式中,本发明提供了式I(a)和式I(b)所示化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物:
式I(a) 式I(b)
其中,R1选自-CN,-O-甲基,-O-乙基,-O-丙基,-O-异丙基,-O-丁基,-O-叔丁基,-O-异戊基,1-萘氧基,2-萘氧基,4-吲哚氧基,5-吲哚氧基,5-异喹啉氧基。
另一优选实施方式中,本发明提供了式I(c)和式I(d)所示化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物:
式I(c) 式I(d)
其中,R1选自-CN,-O-甲基,-O-乙基,-O-丙基,-O-异丙基,-O-丁基,-O-叔丁基,-O-异戊基,1-萘氧基,2-萘氧基,4-吲哚氧基,5-吲哚氧基,5-异喹啉氧基。
另一优选实施方式中,本发明提供了式I(e)和式I(f)所示化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物:
式I(e) 式I(f)
其中,R1选自-CN,-O-甲基,-O-乙基,-O-丙基,-O-异丙基,-O-丁基,-O-叔丁基,-O-异戊基,1-萘氧基,2-萘氧基,4-吲哚氧基,5-吲哚氧基,5-异喹啉氧基。
另一优选实施方式中,本发明提供了式I(g)和式I(h)所示化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物:
式I(g) 式I(h)
其中,n是2或3;R1选自-CN,-O-甲基,-O-乙基,-O-丙基,-O-异丙基,-O-丁基,-O-叔丁基,-O-异戊基,1-萘氧基,2-萘氧基,4-吲哚氧基,5-吲哚氧基,5-异喹啉氧基;R3选自-OH,-O-CH3,-O-CH2-CH3,-NH2,-N(-CH3)2,-NH(-CH2-苯基),-NH(-苯基),-CN
式I化合物的药学上认可的盐包括其药学上认可的酸加成盐,金属盐,铵盐,有机胺加成盐,氨基酸加成盐等。
本发明不仅包括以上所述的化合物,而且还包括双环化合物的类似物。
而且,本发明尤为优选的实施方式中提供了以下化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物:
N-(4-吲哚-5-基氧基苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
N-(4-吲哚-4-基氧基苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-萘氧基苯基)羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(2-萘氧基)苯基)羧酰胺
N-(4-(5-异喹啉氧基)苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-苯氧基苯基)羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(3-哌啶基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
{4-[6-甲氧基-7-(3-吗啉-4-基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(3-吗啉-4-基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-(1,2,3,4-四唑-2-基)乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-(1,2,3,4-四唑基)乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-(1,2,3,4-四唑基)乙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基)羧酰胺
{4-[6-甲氧基-7-(2-(1,2,3,4-四唑-2-基)乙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基)羧酰胺
(4-{7-[3-(4,4,-二氟哌啶基)丙氧基]-6-甲氧基喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
{4-[6-甲氧基-7-(3哌嗪基丙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基)羧酰胺
N-(4-氰基苯基)(4-{6-甲氧基-7-[3-(4-甲基哌嗪基)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(3-(1-硫代吗啉代)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
(4-{7-[3-(1,1-二氧(1-硫代吗啉代)丙氧基]-6-甲氧基-喹唑啉-4-基)-N-(4-氰基苯基)羧酰胺
N-(4-氰基苯基)[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-(甲基乙氧基)苯基]羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-萘氧基苯基)羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-吲哚-4-基氧基苯基)羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-苯氧基苯基)羧酰胺
N-(4-氰基苯基)[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-酰胺
[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-N-(4-萘氧基苯基)羧酰胺
N-(4-吲哚-4-基氧基苯基)[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-N-(4-苯氧基苯基)羧酰胺
N-(4-氰基苯基)[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]-N-(4-萘氧基苯基)羧酰胺
N-(4-吲哚-4-基氧基苯基)[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]-N-(4-苯氧基苯基)羧酰胺
(4-{6-甲氧基-7-[3-(2-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
(4-{6-甲氧基-7-[3-(4-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基)(4-{6-甲氧基-7-[3-(2-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
N-(4-氰基苯基)(4-{6-甲氧基-7-[3-(4-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
{4-[7-(2-羟基-3-哌啶基丙氧基)-6-甲氧基喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基]羧酰胺
{4-[7-(2-氟-3-哌啶基丙氧基)-6-甲氧基喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-(6-甲氧基-7-{3-[(2-甲基丙基)磺酰基]丙氧基}喹唑啉-4-基)哌嗪基]-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-{6-甲氧基-7-[3-(丙基磺酰基)丙氧基]喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
4-({4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羰基氨基)苯甲酸甲酯
N-(4-乙酰基基苯基){4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
N-(4-溴苯基){4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(三氟甲基)苯基]羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-甲基苯基)羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基磺酰基)苯基]羧酰胺
N-(4-氟苯基){4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
4-({4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羰基氨基苯甲酸
化合物的制备
可按照1998年9月12日公开的WO98/14431所述的方法来制备本发明的化合物,起始物的制备或获取也如其所述。除了反应位点之外,可以根据需要采用诸如卤素、低级烷氧基、低级硫代烷基、低级烷基磺酰基氧基、芳基磺酰基氧基等离去基团进行保护,然后去保护。合适的氨基保护基可参见T.W.Greene,《有机合成中的保护基》,John Wiley&Sons Inc.(1981),例如乙氧基羰基,叔丁氧基羰基,乙酰基和苄基。保护基的引入和去除可参照有机合成化学领域的常规技术(例如,T.W.Greene,《有机合成中的保护基》,John Wiley&Sons Inc.(1981))。
在上述过程中,如果所定义的基团在反应条件下发生改变,或者不适合所采用的方法,则可采用有机合成化学领域引入和去除保护基的常规方法来制取所需的化合物(例如参见T.W.Greene,《有机合成中的保护基》,John Wiley&SonsInc.(1981)等)。取代基中官能团的转化,除上述方法之外,还可按已知方法进行(例如R.C.Larock,《有机转化大观》(1989)),而且,某些式I所示的活性化合物可以作为中间体用于进一步合成新的式I所示其他衍生物。
以上过程中的中间体和所需化合物可用有机合成化学中的常规精制方法来分离和纯化,例如:中和,过滤,洗涤,干燥,浓缩,重结晶,以及各种层析法。所得中间体无需纯化即可直接用于下一步反应。
某些式I化合物可能存在互变异构体,本发明涵盖包括互变异构体及其混合物在内的所有可能存在的异构体。如果因为有手性碳原子而存在两种不同的对映体,则本发明包括这两种对映体及其拆分方法。
如果所需的是式I化合物的盐,而产物形式正是这种盐,则可以直接纯化获取该盐。如果产物是式I化合物的游离形式,而所需的是其盐,则可将式I化合物溶解或悬浮在合适的有机溶剂中,然后加入酸或碱来成盐。
以下非限定性反应方案I和II是制备本发明化合物的优选实施方式。
方案I
以上合成叔丁基-4-[6-甲氧基-7-(苯基甲氧基)喹唑啉-4-基]-哌嗪羧酸酯化合物的方法提供了可用于合成各种前述式I化合物的中间体(可调整该过程来产生双环位置异构体)。将香草酸苄基化,然后用发烟硝酸在100℃左右硝化。用氯化锡之类还原剂还原硝基,然后用甲酰胺之类碱进行高温-以100-200℃为佳-环化,从而得到喹唑啉酮。用诸如亚硫酰氯、草酰氯和磷酰氯等卤化剂在诸如甲苯或四氯化碳等溶剂中处理喹唑啉酮,从而合成得到4-Cl-喹唑啉。在合适的溶剂中,例如在异丙醇、乙腈或THF中,室温下或回流1-6小时,在三乙胺或吡啶类碱存在下,用Boc-哌嗪处理4-Cl-喹唑啉,于是得到所示中间体。
方案II
方案II是由方案I或其他方法所得中间体合成各种取代脲中间体的方法。在氢化条件下将方案I所得中间体(或其双环位置异构体)去苄基,然后用各种取代卤代烷进行烷基化。用三氟乙酸去除Boc保护基,然后用各种异氰酸酯处理,从而获得最终的脲化合物。如果无法购得异氰酸酯,则可用光气处理哌嗪中间体,得到氨基甲酰氯中间体,然后与各种取代苯胺反应。也可以用氯甲酸对硝基苯酯处理哌嗪中间体,得到氨基甲酸硝基苯酯,然后可用各种苯胺处理从而获得所需的脲。如果所述脲化合物具有NH2端基(或者,该氨基上的一个或多个氢原子被可置换的取代基所取代),则该化合物可用作中间体来合成以-NH-苯基-R1封端的脲化合物。或者,如果需要苯基上为另外的R1基团,则可以在偶合后通过取代对位的可置换离去基团获得特定的式I所示R1取代基。
以上所述只是说明本发明制备所述化合物的优选实施方式。根据以上所述的反应方案和本发明化合物的结构,其他方法和调整对于本领域技术人员来说显而易见。这些方法都包括在本发明范围内。
而且,式I化合物及其药学上认可的盐可能以与水(水合物)或各种溶剂的加成物形式存在,这些也在本发明范围内。
以下非限定性实施例有助于更好地理解本发明。
实施例1
按照方案I和II所示,制备中间体4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]-哌嗪羧酸叔丁酯:
步骤A:向香草酸(25g,149mmol)的DMF(300ml)溶液中加入K2CO3(102.7g,744mmol,BnBr(44.2g,372mmol),所得的悬浮液于室温下搅拌过夜。过滤反应混合物,加入EtOAc,所得溶液用盐水洗涤,干燥,浓缩。经硅胶层析纯化得55g(96%)中间体产物。MS(ES)349(M+H)+。
步骤B:-10℃,向步骤A所得苄基保护的产物(20g,57.4mmol)的CH2Cl2溶液(100ml)中缓慢加入乙酸(100ml)。向所得冷溶液中缓慢加入浓HNO3(25.8ml,574.4mmol),让反应升至室温,然后在100℃回流过夜。次日,将反应混合物倒入冰中,用EtOAc萃取产物,用盐水洗涤,用MgSO4干燥。真空挥发溶剂,得到所需中间体产物的黄色固体(21.8g,96.5%)。MS(ES)416(M+Na)。
步骤C:向步骤B所得硝基化合物(10.9g,27.7mmol)的EtOAc溶液(100ml)中加入SnCl2.H2O(18.7g,83.1mmol),反应混合物在50℃加热过夜。将反应混合物冷却后用硅藻土过滤,滤液用10%NaHCO3洗涤,用EtOAc萃取。干燥有机层,蒸发溶剂,得到中间体氨基化合物的棕色固体(9.5g,95%)。MS(ES)364(M+H)。
步骤D:将步骤C所得氨基产物(3g,8.3mmol)溶于甲酰胺(20ml),向其中加入甲酸铵(781mg,12.4mmol),反应混合物在150℃加热4小时。期间,HPLC(高效液相层析)证实起始物完全耗尽,冷却后,将反应混合物倒入水中,得到奶油色沉淀。过滤收集沉淀,即为所需中间体,环化的7-苄基氧基-6-甲氧基-4-喹唑啉酮(1.9g,81%)。MS(ES)283(M+H)。
步骤E:7-苄基氧基-6-甲氧基-4-喹唑啉酮(1g,3.5mmol,步骤D所得),亚硫酰氯(5ml)和DMF(5滴)的混合物加热回流4小时。冷却后,蒸发去除过量亚硫酰氯,所得残留物与甲苯共沸蒸馏,得到中间体4-氯-6-甲氧基-7-苄基氧基喹唑啉黄色固体(652mg,62%)。MS(ES)301(M+H)。
步骤F:向4-氯-6-甲氧基-7-苄基氧基喹唑啉(1.8g,6mmol)的THF(20ml)溶液中加入Boc-哌嗪(2.2g,12mmol),然后加入DIEA(4.2ml,24mmol),50℃加热反应过夜。蒸发去除溶剂,将残留物溶于水,用EtOAc萃取。EtOAc层经干燥,过滤和蒸发,得中间体4-[6-甲氧基-7-苯基甲氧基)喹唑啉-4-基]哌嗪羧酸叔丁酯白色固体(2.2g,81%)。MS(ES)451(M+H)。
步骤G:将步骤F所得苄基氧基化合物(500mg,1.1mmol)溶于EtOH(5ml),向其中加入Pd(OH)2/C(50mg),将混合物在50psi H2压力的Parr氢化仪上放置过夜。用硅藻土过滤反应混合物,用EtOH洗涤,蒸发溶剂,得去苄基化中间体(400mg,98%)。MS(ES)361(M+H)。
步骤H:向4-[6-甲氧基-7-苯基甲氧基)喹唑啉-4-基]哌嗪羧酸叔丁酯(1.8g,5mmol)和Cs2CO3(3.3g,10mmol)的DMF溶液(10ml)中加入甲苯磺酸1-氯乙酯(1.8ml,10mmol)。室温下搅拌反应过夜。蒸发溶剂,粗残留物经RP-HPLC(反相高效液相层析)纯化得中间体4-[6-甲氧基-7-(2-氯乙氧基)喹唑啉-4-基]哌嗪羧酸叔丁酯(850mg,40%)。MS(ES)423(M+H)。
步骤I:向步骤H所得起始物(450mg,1.2mmol)的DMF溶液(10ml)中加入哌啶(1.2ml,12mmol),80℃搅拌反应过夜。蒸发溶剂,粗残留物经RP-HPLC纯化得4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪羧酸叔丁酯(310mg,55%)。MS(ES)472(M+H)。
实施例2
用实施例1所得中间体,按照方案II所示,制备N-(4-氰基苯基){4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪}羧酰胺:
向4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪羧酸叔丁酯(实施例1步骤I所得,111mg,0.3mmol)中加入4N HCl/二噁烷(1ml),室温下搅拌反应1小时。蒸发溶剂,与戊烷共沸蒸馏数次后得去Boc产物,即去除了Boc保护基的产物。向所得残留物中加入DMF(2ml),然后加入异氰酸4-氰基苯酯(75mg,0.45mmol),室温下搅拌反应过夜。蒸发溶剂,残留物经RP-HPLC纯化,得所需产物N-(4-氰基苯基){4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪}羧酰胺白色固体(89mg,59%)。MS(ES)516(M+H)。
实施例3-4
按照实施例1和2所述方法制备N-(4-氰基苯基){4-[6-甲氧基-7-(2-(甲氧基)乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺:
所不同的是用1-溴乙基甲基醚取代甲苯磺酸1-氯乙酯作为烷化剂,得率与实施例1和2相近。
根据以下实施例所述的试验测定了本发明化合物的药学活性。
生物学试验1
化合物对血小板衍生类生长因子β-PDGF受体自磷酸化的抑制作用
(1)HR5磷酸化试验
HR5细胞系是一个经基因工程处理而过量表达人β-PDGFR的CHO细胞系,可以向ATCC获取。HR5细胞系内β-PDGFR的表达水平约为5×104受体/细胞。为了进行本发明的磷酸化试验,在标准组织培养条件下将HR5细胞在96格微滴板上培养至铺满,然后无血清培养16小时。37℃,不加待测化合物,或逐步升高待测化合物浓度(0.01-30μM),培养静息细胞30分钟,然后加入8nM PDGF BB培养10分钟。在100mM Tris,pH7.5,750mM NaCl,0.5%Triton X-100,10mM焦磷酸钠,50mM NaF,10μg/ml抑蛋白酶肽,10μg/ml亮抑蛋白酶肽,1mM苯基甲基磺酰氟,1mM钒酸钠中裂解细胞,15,000×g离心5分钟以澄清裂解液。将澄清后的裂解液转移到另一微滴板上,板上各格中已预涂了500ng/格的1B5B11抗β-PDGFR mAb,室温下孵育2小时。用结合缓冲液(0.3%明胶,25mM HepespH7.5,100mM NaCl,0.01%Tween-20)洗涤3次,然后加入250ng/ml兔多克隆抗磷酸酪氨酸抗体(Transduction Laboratory),37℃孵育60分钟。然后,各格用结合缓冲液洗涤3次,与1μg/ml辣根过氧化物酶偶联的抗兔抗体(Boehringer Mannheim)一起37℃孵育60分钟。各格洗涤后加入ABTS(Sigma),在650nm处监测底物形成速度。实验结果以与不接触本发明化合物的对照细胞相比的IC50表示(表示本发明化合物抑制50%的PDGF受体磷酸化时的浓度),并。
本发明化合物在HR5试验中测得的IC50值列于表1。
(2)MG63磷酸化试验
MG63细胞系是一个人骨肉瘤肿瘤细胞系,可向ATCC获取。本试验测定的是MG63细胞内内源性β-PDGFR磷酸化作用。试验条件与HR5细胞试验相同,不同的是在有或没有45%人血浆存在下给予PDGF-BB刺激。HR5试验的结果以与不接触本发明化合物的对照细胞相比的IC50表示(表示本发明化合物抑制50%的PDGF受体磷酸化时的浓度)。
本发明化合物在MG63试验中测得的IC50值列于表1。
以下表1中是实施例2和4化合物的试验结果。
表1
实施例化合物 | MG63w/人血浆IC50(μM) | HR5 |
实施例2 | 0.080 | 0.360 |
实施例4 | 0.700 | 1.5 |
生物学试验2
对平滑肌细胞的生长抑制
由猪的大动脉分离血管平滑肌细胞用于试验。将细胞加入96格微滴板的各格中(8000细胞/格),在Dulbeccois改进的Eagle氏培养基(DMEM;NissuiPharmaceutical Co.,Ltd.)中培养4天。然后,再在含0.1%FBS的DMEM中培养3天,在细胞生长稳定期进行同步化。
向各格中加入含0.1%FBS的DMEM和不同浓度的待测样品,用PDGF-BB(Sigma,终浓=20ng/ml)诱导细胞生长。培养3天后,用细胞生长试验试剂盒(Boehringer Mannheim)按照XTT法(免疫学方法杂志,142,257-265(1991))测定细胞生长,用以下公式计算细胞生长分数:
细胞生长分数=100×{1-(M-PO)/(P100-PO)}其中,P100=受PDGF-BB刺激时XTT试剂的吸光度;PO=无PDGF-BB刺激时XTT试剂的吸光度;M=加样品后受PDGF-BB刺激时XTT试剂的吸光度。
实验结果用待测化合物抑制50%细胞生长时的浓度表示(IC50)。
生物学试验3
对血管内膜肥厚的抑制作用
用戊巴比托钠麻醉(50mg/kg,i.p.)雄性SD大鼠(体重375-445g,Charles River,golden standard),沿中线切开颈部,在左外颈动脉内逆向插入气球插管(2F,Edwards Laboratory)。以上处理重复7次后,抽出插管,连接左外颈动脉,缝合创口。如欲腹膜内给药,将待测化合物悬浮在0.5%Tween80的氯化钠水溶液中至浓度为20mg/ml,如欲经口给药,则将待测化合物悬浮于0.5%甲基纤维素400的NaCl溶液中至浓度为6mg/ml。如果是腹膜内给药,每日给予悬浮液1次,如果是经口给药,则每日1-2次,自气球插管手术前一天开始,持续15天。气球手术后的第14天,将大鼠杀死,摘取其左颈动脉。用福尔马林固定组织,石蜡包封后切片,然后进行Elastica Wangeeson染色。用图像分析仪(Luzex F,NIRECO)测定血管组织(内膜和中膜)截面面积,以内膜/中膜面积比(I/M)表征血管内膜肥厚程度。
所得结果显示,本发明化合物显著抑制血管内膜肥厚。
生物学试验4
用大鼠佐剂关节炎模型进行的评价
用玛瑙验钵将分支杆菌(Difco Laboratories Inc.)死细胞磨碎,悬浮在液体石蜡中,至最终浓度为6.6mg/ml,然后进行高压蒸气消毒。然后,给雌性8周龄Lewis大鼠(Charles River Japan)(6只一组)右后足垫皮下注射100ml该悬浮液以诱导佐剂关节炎。将待测化合物悬浮于0.5%甲基纤维素溶液至3mg/ml,从临诱导前开始,每日一次经口给予100ml/g体重该悬浮液,一周5日。对照组仅给予0.5%甲基纤维素溶液。正常组不给予佐剂或待测化合物。待测化合物给药持续到佐剂诱导后第18天。在第17天,计数外周血中的白细胞数,在第18天,收集全血,然后解剖。
测定和评价体重随时间的变化,后足水肿随时间的变化,脾和胸腺重量,外周血白细胞数,尿中羟脯氨酸含量,尿中葡糖氨基聚糖含量,血清SH浓度,血清一氧化氮浓度和血清粘蛋白浓度。用大鼠后足水肿测定仪(TK-101,Unicom)测定两后足的体积。用自动多道血细胞计数仪(Sysmex K-200,Toa Iyo Denshi Co.,Ltd.)计数外周血白细胞数。按Ikeda等在Tokyo Metropolitan Research LaboratoriesP.H.年度报告,36,277(1985)所述的方法测定尿中羟脯氨酸含量,按Moriyama等,Hinyo Kiyo,40,565(1994)和Klompmakers等,《分析生物化学》,153,80(1986)所述的方法测定葡糖氨基聚糖含量。按Miesel等《炎症》,17,595(1993)所述方法测定血清SH浓度,按Tracey等,《药学和实验治疗学杂志》272,1011(1995)所述方法测定血清一氧化氮浓度。用Aspro GP试剂盒(Otsuka Pharmaceutical Co.,Ltd.)测定粘蛋白浓度。按照以下公式计算抑制百分比:
%抑制={(对照组-化合物处理组)/(对照组-正常组}×100
以上试验所得结果显示,本发明化合物可抑制佐剂关节炎的发生。
生物学试验5
对肾小球膜增殖性肾小球肾炎模型的活性
给雄性Wister-Kyoto大鼠(Charles River Japan,160g,6只一组)尾静脉注射1.0mg/kg抗大鼠Thy-1.1单克隆抗体OX-7(Sedaren)。将待测化合物悬浮于0.5%甲基纤维素溶液中,每日两次给大鼠注射所得悬浮液,从给予OX-7的前一天开始,持续7天。给予OX-7后第7天,当肾小球膜细胞生长和胞外基质肥厚变得明显时,摘取左肾,用20%缓冲福尔马林固定6小时,然后石蜡包封,切片。用抗增殖细胞核内抗原的抗体PC10(DAKO)对所得切片进行免疫组织染色。用二氨基联苯胺作为展色剂用Methyl Green溶液进行对比染色后,将石蜡切片密封。在一肾切片中可观察到半个肾小球,计数一个肾小球内的增殖细胞核内抗原阳性细胞数。用Wilcoxon试验评价差异显著性。
结果显示,本发明化合物能够缓解肾小球膜增殖性肾小球肾炎。
式I化合物及其药学上认可的盐可以原形直接给药,但通常以人用和兽用药物组合物形式给药为佳。
给药途径优选疗效最佳的。例如,给药途径可以是口服或直肠内、口内、皮下、肌内或静脉内等非口服途径。
剂型可例如胶囊、片剂、颗粒剂、粉剂、糖浆、乳液、栓剂和注射剂。
配制适合口服的液体组合物,例如乳液和糖浆,可采用水,蔗糖、山梨糖和果糖等糖,聚乙二醇和丙二醇等多元醇,芝麻油、橄榄油和大豆油等油,苯甲酸之类防腐剂,草莓香精和薄荷等调味剂等。
制备胶囊,片剂,粉剂和颗粒剂所用的赋形剂有例如乳糖,葡萄糖,蔗糖和甘露糖,淀粉和藻酸钠等崩解剂,硬脂酸镁和滑石粉等润滑剂,聚乙烯醇、羟丙基纤维素和明胶等粘合剂,脂肪酸酯等表面活性剂,甘油等增塑剂,等等。
非口服组合物最好包含消毒过的水性制剂,其中含有与受主血液等渗的活性化合物。例如,可用含有盐溶液,葡萄糖溶液或盐溶液和葡萄糖溶液混合物的载体来制备注射剂。
局部用组合物可通过将活性化合物溶于或悬浮于一种或多种溶剂中来制备,所述溶剂例如矿物油,凡士林和多元醇,或是其他用于局部用药的基质。
肠内给药的组合物可用诸如可可脂、氢化脂肪和氢化脂肪羧酸等常用载体来制备,并制成栓剂。
非口服组合物还可以包含一种或多种以下常用于制备口服组合物的添加剂:乙二醇,油,调味剂,防腐剂(包括抗氧化剂),赋形剂,崩解剂,润滑剂,粘合剂,表面活性剂和增塑剂。
每一种式I化合物或其药学上认可的盐的有效量和给药方案取决于给药途径,患者年龄和体重,疾病类型和程度。然而,一般说来,式I化合物或其药学上认可的盐的适当剂量约为0.01-1000mg/成人/日,以5-500mg/成人/日为佳,可以一次或分次给予。
本发明的化合物都可以直接作为激酶抑制剂用于治疗哺乳动物激酶依赖性疾病,尤其是与酪氨酸激酶相关的疾病。尤其好的是IC50为10nM-10μM的化合物,10nM-1μM的更好,小于1μM的最好。
可以选择对三种蛋白质激酶(例如,催化酪氨酸磷酸化的激酶,催化酪氨酸和苏氨酸磷酸化的激酶,和催化苏氨酸磷酸化的激酶)之一具有特异性抑制活性的本发明具体化合物。酪氨酸激酶依赖性疾病包括因酪氨酸激酶活性异常导致或维持的超增殖性机能不良,例如牛皮癣,肺纤维化,肾小球肾炎,癌症,动脉硬化和抗血管生成(例如肿瘤生长和糖尿病性肾病)。目前尚不完全清楚其他激酶与特定疾病之间的关联性。然而,具有特异性PTK抑制性的化合物具有治疗效用。还发现,其他激酶也一样。懈皮素,染料木苷和十字孢碱都是PTK抑制剂,它们能够抑制除酪氨酸激酶以外的多种蛋白质激酶。然而,因为它们没有特异性,所以毒性很高。所以,用测定细胞毒性的常规试验可鉴定出因没有特异性而会造成不良副作用的PTK抑制剂(或其他激酶的抑制剂)。
根据以上所述可以确信本领域普通技术人员能够实施本发明。以上实施例没有限定意义,因为本领域普通技术人员根据本文所述很容易预见到符合本发明总旨的其他改换和变化形式。这些改换和变化都属于本发明范围之内。
虽然以上为了有助于清楚地理解本发明而对其进行了详细的描述,但对本领域普通技术人员来说显而易见的是在本发明范围内,根据本发明构思,还包涵着许多修改形式和等效形式。应当认为,以上论述和实施例只是对优选实施方式的详细描述。前文中引述的专利、杂志论文等文献都为本发明全文参考引用。
Claims (12)
1.以下所示含氮杂环化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物:
其中,R1选自:-CN,-X,-CX3,-R5,-CO2R5,-C(O)R5,-SO2R5,-O-C1-8直链或支链烷基,-O-苯基,-O-萘基,-O-吲哚基和-O-异喹啉基;
X是卤素;
R5是H或C1-8直链或支链烷基;
R2和R4各自选自:-O-CH3,-O-CH2-CH3,-O-CH2-CH=CH2,-O-CH2-C≡CH,-O(CH2)n-SO2-R5,-O-CH2-CH(R6)CH2-R3和-O(-CH2)n-R3;
R6是-OH,-X或C1-8直链或支链烷基;
n是2或3;
R3选自:-OH,-O-CH3,-O-CH2-CH3,-NH2,-N(-CH3)2,-NH(-CH2-苯基),-NH(-苯基),-CN,
2.如权利要求所述的化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物,其中的R1选自:-CN,-O-甲基,-O-乙基,-O-丙基,-O-异丙基,-O-丁基,-O-叔丁基,-O-异戊基,1-萘氧基,2-萘氧基,4-吲哚氧基,5-吲哚氧基,5-异喹啉氧基,以及它们的位置异构体和类似物。
3.如权利要求2所述的化合物及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物,其中的R2与R4不同,且其中之一为-O-CH3。
8.如权利要求1所示的化合物,及其药学上认可的异构体、盐、水合物、溶剂化物和前药衍生物,选自:
N-(4-吲哚-5-基氧基苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
N-(4-吲哚-4-基氧基苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-萘氧基苯基)羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(2-萘氧基)苯基)羧酰胺
N-(4-(5-异喹啉氧基)苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-苯氧基苯基)羧酰胺
{4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-甲氧基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-哌啶基乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(3-哌啶基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
{4-[6-甲氧基-7-(3-吗啉-4-基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(3-吗啉-4-基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-(1,2,3,4-四唑-2-基)乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(2-(1,2,3,4-四唑基)乙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(2-(1,2,3,4-四唑基)乙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基)羧酰胺
{4-[6-甲氧基-7-(2-(1,2,3,4-四唑-2-基)乙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基)羧酰胺
(4-{7-[3-(4,4,-二氟哌啶基)丙氧基]-6-甲氧基喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
{4-[6-甲氧基-7-(3-哌嗪基丙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基)羧酰胺
N-(4-氰基苯基)(4-{6-甲氧基-7-[3-(4-甲基哌嗪基)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
N-(4-氰基苯基){4-[6-甲氧基-7-(3-(1-硫代吗啉代)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
(4-{7-[3-(1,1-二氧(1-硫代吗啉代)丙氧基]-6-甲氧基-喹唑啉-4-基)-N-(4-氰基苯基)羧酰胺
N-(4-氰基苯基)[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-(甲基乙氧基)苯基]羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-萘氧基苯基)羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-吲哚-4-基氧基苯基)羧酰胺
[4-(7-乙氧基-6-甲氧基喹唑啉-4-基)哌嗪基]-N-(4-苯氧基苯基)羧酰胺
N-(4-氰基苯基)[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-酰胺
[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-N-(4-萘氧基苯基)羧酰胺
N-(4-吲哚-4-基氧基苯基)[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(6-甲氧基-7-丙-2-烯基氧基喹唑啉-4-基)哌嗪基]-N-(4-苯氧基苯基)羧酰胺
N-(4-氰基苯基)[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]-N-(4-萘氧基苯基)羧酰胺
N-(4-吲哚-4-基氧基苯基)[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]羧酰胺
[4-(6-甲氧基-7-丙-2-炔基氧基喹唑啉-4-基)哌嗪基]-N-(4-苯氧基苯基)羧酰胺
(4-{6-甲氧基-7-[3-(2-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
(4-{6-甲氧基-7-[3-(4-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
N-(4-氰基苯基)(4-{6-甲氧基-7-[3-(2-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
N-(4-氰基苯基)(4-{6-甲氧基-7-[3-(4-甲基哌啶基)丙氧基]喹唑啉-4-基}哌嗪基)羧酰胺
{4-[7-(2-羟基-3-哌啶基丙氧基)-6-甲氧基喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基]羧酰胺
{4-[7-(2-氟-3-哌啶基丙氧基)-6-甲氧基喹唑啉-4-基]哌嗪基}-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-(6-甲氧基-7-{3-[(2-甲基丙基)磺酰基]丙氧基}喹唑啉-4-基)哌嗪基]-N-[4-(甲基乙氧基)苯基]羧酰胺
[4-{6-甲氧基-7-[3-(丙基磺酰基)丙氧基]喹唑啉-4-基}哌嗪基)-N-[4-(甲基乙氧基)苯基]羧酰胺
4-({4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羰基氨基)苯甲酸甲酯
N-(4-乙酰基基苯基){4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
N-(4-溴苯基){4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(三氟甲基)苯基]羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-(4-甲基苯基)羧酰胺
{4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}-N-[4-(甲基磺酰基)苯基]羧酰胺
N-(4-氟苯基){4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羧酰胺
4-({4-[6-甲氧基-7-(3-吡咯烷基丙氧基)喹唑啉-4-基]哌嗪基}羰基氨基苯甲酸
9.药物组合物,包含有效量的权利要求1所述含氮杂环化合物或其药学上认可的盐,和药学上认可的稀释剂或载体。
10.抑制患者体内PDGF受体磷酸化的方法,包括给予患者权利要求9所述的组合物。
11.抑制患者体内异常细胞生长和细胞迁移从而预防或治疗细胞增殖性疾病的方法,包括给予患者权利要求9所述的组合物。
12.如权利要求11所述的方法,所述是细胞增殖性疾病选自动脉硬化、血管再梗阻,再狭窄,癌症和血管球性硬化症。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22612200P | 2000-08-18 | 2000-08-18 | |
US60/226,122 | 2000-08-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1633431A true CN1633431A (zh) | 2005-06-29 |
CN100358890C CN100358890C (zh) | 2008-01-02 |
Family
ID=22847639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018173527A Expired - Fee Related CN100358890C (zh) | 2000-08-18 | 2001-08-17 | 喹唑啉衍生物类激酶抑制剂 |
Country Status (25)
Country | Link |
---|---|
US (5) | US6982266B2 (zh) |
EP (3) | EP2277877A1 (zh) |
JP (1) | JP5073147B2 (zh) |
KR (1) | KR100831116B1 (zh) |
CN (1) | CN100358890C (zh) |
AT (1) | ATE402169T1 (zh) |
AU (1) | AU8544901A (zh) |
BR (1) | BR0113356A (zh) |
CA (1) | CA2426440C (zh) |
CY (1) | CY1110460T1 (zh) |
CZ (1) | CZ304061B6 (zh) |
DE (1) | DE60134990D1 (zh) |
DK (1) | DK1315715T3 (zh) |
EA (1) | EA005809B1 (zh) |
ES (1) | ES2311023T3 (zh) |
HK (1) | HK1057206A1 (zh) |
HU (1) | HU228668B1 (zh) |
IL (2) | IL154514A0 (zh) |
MX (1) | MXPA03001359A (zh) |
NO (1) | NO323782B1 (zh) |
NZ (1) | NZ524461A (zh) |
PT (1) | PT1315715E (zh) |
SI (1) | SI1315715T1 (zh) |
WO (1) | WO2002016351A1 (zh) |
ZA (1) | ZA200301510B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102942529A (zh) * | 2012-11-09 | 2013-02-27 | 贵州大学 | 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用 |
CN103288760A (zh) * | 2013-05-16 | 2013-09-11 | 苏州明锐医药科技有限公司 | 卡奈替尼的制备方法 |
CN106083715A (zh) * | 2016-06-01 | 2016-11-09 | 谢阳 | 一种喹啉、喹唑啉类化合物及其药物组合物和应用 |
CN111773440A (zh) * | 2020-05-22 | 2020-10-16 | 南京大学 | 一种基于类酶催化反应的抗凝血材料 |
CN114920704A (zh) * | 2019-07-26 | 2022-08-19 | 暨南大学 | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2361582T3 (es) | 2000-08-18 | 2011-06-20 | Millennium Pharmaceuticals, Inc. | Compuestos [(quinazolin-4-il)piperazin-4-il]tiocarboxamida como inhibidores de la fosforilación de un receptor de pdgf. |
EP1309569B1 (en) | 2000-08-18 | 2010-10-06 | Millennium Pharmaceuticals, Inc. | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors |
EA005809B1 (ru) * | 2000-08-18 | 2005-06-30 | Милленниум Фармасьютикалз, Инк. | Производные хиназолина в качестве ингибиторов киназы |
ATE502928T1 (de) | 2000-11-01 | 2011-04-15 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
AU2002254152A1 (en) | 2001-03-08 | 2002-09-24 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
IL162203A0 (en) | 2001-12-27 | 2005-11-20 | Theravance Inc | Indolinone derivatives useful as protein inase inhibitors |
AU2003256922A1 (en) * | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted heterocyclic compounds as modulators of the ccr5 receptor |
US7195876B2 (en) | 2002-08-09 | 2007-03-27 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
WO2006002422A2 (en) * | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
WO2006116733A2 (en) * | 2005-04-28 | 2006-11-02 | Supergen, Inc. | Protein kinase inhibitors |
CA2612459A1 (en) * | 2005-07-20 | 2007-01-25 | Millennium Pharmaceuticals, Inc. | New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide |
EP1991531A1 (en) * | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
UA95641C2 (en) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
EP2077842A2 (en) | 2006-10-31 | 2009-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
JP5250901B2 (ja) * | 2007-02-23 | 2013-07-31 | 学校法人慶應義塾 | アニリノキナゾリン系化合物及びその用途 |
AU2008240188A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
WO2010059239A2 (en) | 2008-11-21 | 2010-05-27 | Millennium Pharmaceuticals, Inc | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
WO2015009889A1 (en) | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3280708B1 (en) | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
MX2017013275A (es) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos. |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
CA3005089A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
KR20210003780A (ko) | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | Axl 키나제 억제제 및 그의 용도 |
CN108570039B (zh) * | 2018-04-25 | 2022-09-23 | 上海美迪西生物医药股份有限公司 | 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用 |
KR20210146290A (ko) | 2019-02-12 | 2021-12-03 | 스미토모 다이니폰 파마 온콜로지, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
TW225528B (zh) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
EP0882717B1 (en) * | 1996-10-01 | 2010-09-08 | Kyowa Hakko Kirin Co., Ltd. | Nitrogenous heterocyclic compounds |
ATE496035T1 (de) * | 1998-03-31 | 2011-02-15 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
EP1309569B1 (en) | 2000-08-18 | 2010-10-06 | Millennium Pharmaceuticals, Inc. | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors |
ES2361582T3 (es) | 2000-08-18 | 2011-06-20 | Millennium Pharmaceuticals, Inc. | Compuestos [(quinazolin-4-il)piperazin-4-il]tiocarboxamida como inhibidores de la fosforilación de un receptor de pdgf. |
AU2001293207A1 (en) | 2000-08-18 | 2002-03-04 | Cor Therapeutics, Inc. | Nitrogenous heterocyclic compounds |
EA005809B1 (ru) * | 2000-08-18 | 2005-06-30 | Милленниум Фармасьютикалз, Инк. | Производные хиназолина в качестве ингибиторов киназы |
AU2002254152A1 (en) | 2001-03-08 | 2002-09-24 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
AU2002350105A1 (en) * | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US7456189B2 (en) * | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
-
2001
- 2001-08-17 EA EA200300265A patent/EA005809B1/ru not_active IP Right Cessation
- 2001-08-17 US US10/344,736 patent/US6982266B2/en not_active Expired - Fee Related
- 2001-08-17 DK DK01964612T patent/DK1315715T3/da active
- 2001-08-17 AT AT01964612T patent/ATE402169T1/de active
- 2001-08-17 WO PCT/US2001/041752 patent/WO2002016351A1/en active IP Right Grant
- 2001-08-17 MX MXPA03001359A patent/MXPA03001359A/es active IP Right Grant
- 2001-08-17 IL IL15451401A patent/IL154514A0/xx active IP Right Grant
- 2001-08-17 CZ CZ20030765A patent/CZ304061B6/cs not_active IP Right Cessation
- 2001-08-17 KR KR1020037002381A patent/KR100831116B1/ko not_active IP Right Cessation
- 2001-08-17 EP EP10182322A patent/EP2277877A1/en not_active Withdrawn
- 2001-08-17 CA CA2426440A patent/CA2426440C/en not_active Expired - Fee Related
- 2001-08-17 EP EP08075237A patent/EP1964839A3/en not_active Ceased
- 2001-08-17 BR BR0113356-0A patent/BR0113356A/pt active Search and Examination
- 2001-08-17 PT PT01964612T patent/PT1315715E/pt unknown
- 2001-08-17 NZ NZ52446101A patent/NZ524461A/xx not_active IP Right Cessation
- 2001-08-17 EP EP01964612A patent/EP1315715B1/en not_active Expired - Lifetime
- 2001-08-17 HU HU0302615A patent/HU228668B1/hu not_active IP Right Cessation
- 2001-08-17 SI SI200130872T patent/SI1315715T1/sl unknown
- 2001-08-17 JP JP2002521452A patent/JP5073147B2/ja not_active Expired - Fee Related
- 2001-08-17 ES ES01964612T patent/ES2311023T3/es not_active Expired - Lifetime
- 2001-08-17 DE DE60134990T patent/DE60134990D1/de not_active Expired - Lifetime
- 2001-08-17 AU AU8544901A patent/AU8544901A/xx active Pending
- 2001-08-17 CN CNB018173527A patent/CN100358890C/zh not_active Expired - Fee Related
-
2003
- 2003-02-17 NO NO20030747A patent/NO323782B1/no not_active IP Right Cessation
- 2003-02-18 IL IL154514A patent/IL154514A/en not_active IP Right Cessation
- 2003-02-26 ZA ZA200301510A patent/ZA200301510B/en unknown
- 2003-11-28 HK HK03108720A patent/HK1057206A1/xx not_active IP Right Cessation
-
2005
- 2005-08-22 US US11/210,028 patent/US7560461B2/en not_active Expired - Fee Related
-
2008
- 2008-10-21 CY CY20081101177T patent/CY1110460T1/el unknown
-
2009
- 2009-05-22 US US12/471,280 patent/US8324205B2/en not_active Expired - Fee Related
-
2012
- 2012-11-02 US US13/667,489 patent/US20130274252A1/en not_active Abandoned
-
2014
- 2014-07-09 US US14/327,312 patent/US20150133439A1/en not_active Abandoned
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102942529A (zh) * | 2012-11-09 | 2013-02-27 | 贵州大学 | 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用 |
CN102942529B (zh) * | 2012-11-09 | 2015-06-24 | 贵州大学 | 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用 |
CN103288760A (zh) * | 2013-05-16 | 2013-09-11 | 苏州明锐医药科技有限公司 | 卡奈替尼的制备方法 |
CN103288760B (zh) * | 2013-05-16 | 2015-02-18 | 苏州明锐医药科技有限公司 | 卡奈替尼的制备方法 |
CN106083715A (zh) * | 2016-06-01 | 2016-11-09 | 谢阳 | 一种喹啉、喹唑啉类化合物及其药物组合物和应用 |
CN114920704A (zh) * | 2019-07-26 | 2022-08-19 | 暨南大学 | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 |
CN114920704B (zh) * | 2019-07-26 | 2023-11-03 | 暨南大学 | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 |
CN111773440A (zh) * | 2020-05-22 | 2020-10-16 | 南京大学 | 一种基于类酶催化反应的抗凝血材料 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1633431A (zh) | 喹唑啉衍生物类激酶抑制剂 | |
CN1129597C (zh) | 杂环化合物和以其为有效成分的抗肿瘤剂 | |
CN100339080C (zh) | 抗病毒大环化合物 | |
CN1183122C (zh) | 二肽腈组织蛋白酶k抑制剂 | |
CN100341876C (zh) | 螺环取代的吡咯并嘧啶化合物 | |
CN1060172C (zh) | 取代的联苯磺酰胺类内皮素拮抗剂 | |
CN1155281A (zh) | 新的嘧啶衍生物及其制备方法 | |
CN1143953A (zh) | 某些稠合n-吡咯甲酰苯胺;一类新的脑gaba受体配体 | |
CN1349524A (zh) | 血管紧张肽原酶抑制剂 | |
CN1265098A (zh) | 抑制因子xa的杂环衍生物 | |
CN1751033A (zh) | 双环杂环类,含所述化合物的药物制剂,其用途及制备方法 | |
CN1216872C (zh) | 喹唑啉衍生物及其药物用途 | |
CN1216547A (zh) | 质子泵抑制剂 | |
CN1208333C (zh) | 主要用于治疗骨质疏松的吲哚衍生物 | |
EP1309569B1 (en) | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | |
CN1245979C (zh) | 含有胃促胰酶抑制剂作为有效成分的预防和治疗皮炎的药物 | |
CN1302292A (zh) | 氨基异喹啉衍生物 | |
CN1283194A (zh) | 抗风湿剂 | |
CN1361781A (zh) | 用于治疗中枢神经系统疾病的噁嗪并咔唑 | |
CN1366459A (zh) | 含有胃促胰酶抑制剂作为活性成分的预防和治疗各种与嗜酸性粒细胞增多有关的疾病的药物 | |
CN1665791A (zh) | 喹唑啉衍生物 | |
CN1798734A (zh) | 作为蛋白激酶抑制剂的新化合物和组合物 | |
AU2001285449B8 (en) | Quinazoline derivatives as kinase inhibitors | |
AU2001285449A1 (en) | Quinazoline derivatives as kinase inhibitors | |
CN1560050A (zh) | 苯氨基嘧啶衍生物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080102 Termination date: 20150817 |
|
EXPY | Termination of patent right or utility model |